Vaccitech (NASDAQ:VACC) Stock Price Down 4.2%

Vaccitech plc (NASDAQ:VACC)’s stock price fell 4.2% during mid-day trading on Tuesday . The company traded as low as $2.51 and last traded at $2.53. 18,050 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 244,643 shares. The stock had previously closed at $2.64.

Vaccitech Stock Performance

The business’s 50 day moving average is $2.75 and its 200-day moving average is $3.14. The firm has a market capitalization of $104.46 million, a price-to-earnings ratio of -1.82 and a beta of -0.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VACC. Janney Montgomery Scott LLC bought a new position in Vaccitech during the 3rd quarter valued at about $46,000. Baird Financial Group Inc. increased its position in Vaccitech by 9.5% in the 2nd quarter. Baird Financial Group Inc. now owns 196,296 shares of the company’s stock valued at $404,000 after acquiring an additional 17,000 shares in the last quarter. Millennium Management LLC increased its position in Vaccitech by 32.8% in the 4th quarter. Millennium Management LLC now owns 40,388 shares of the company’s stock valued at $97,000 after acquiring an additional 9,967 shares in the last quarter. Renaissance Technologies LLC increased its position in Vaccitech by 198.2% in the 2nd quarter. Renaissance Technologies LLC now owns 34,000 shares of the company’s stock valued at $70,000 after acquiring an additional 22,600 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Vaccitech in the 2nd quarter valued at about $31,000. 26.13% of the stock is currently owned by institutional investors and hedge funds.

About Vaccitech

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.